|
Vol. 5, No. 085 |
|
Underwriter: |
|
|
|
Resources: |
.gif) |
Prostate Cancer Therapies All Affect Quality of Life
In This Issue:
LEAD
- Prostate Cancer Therapies All Affect Quality of Life
- Amgen Seeks Additional U.S. Denosumab Approval
- What Every Man Needs to Know About Prostate Health
- Walgreen to Hold Off Selling Genetic Test Kits
WHAT'S NEW AT ZERO
- New Members Elected to ZERO's Board of Directors
- Hearing Set to Push for Increased Research Funding for Prostate Cancer
- 'DASH FOR DAD' Race Series Coming to 12 Cities to Raise Prostate Cancer Awareness
- Join ZERO's DASH FOR DAD Endurance Team at the Marine Corps Marathon on Sunday, Oct. 31
- Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
- Let Congress Know Your Concerns
RESEARCH AND TREATMENT UPDATE
- Prostate Cancer Surveillance: Biopsy Findings Appear Indispensable
- Taxane Analog Shows 'Unequivocal Benefit' in Prostate Mets
- Positive Surgical Margins and Prostate Cancer-Specific Mortality
- New Technology Aids in Prostate Cancer Treatment
|
[Advertisement]
|
Lead
Prostate Cancer Therapies All Affect Quality of Life
While various forms of prostate cancer treatment can have side effects such as sexual function and urinary problems, this study finds none of the treatments seemed to strongly impact men’s overall quality of life such as emotional well-being and daily physical tasks.
Amgen Seeks Additional U.S. Denosumab Approval
Amgen is seeking FDA’s approval to market its drug, denosumab, for reducing bone fractures in patients with advanced prostate cancer.
What Every Man Needs to Know About Prostate Health
“Prostate health is one of the keys to (men’s) overall well-being, not to mention their families’ future,” advises this article about the need for regular PSA testing, proper diet, and other safeguards.
Walgreen to Hold Off Selling Genetic Test Kits
FDA raises concerns about the pharmacy chain’s plan to sell over-the-counter genetic testing kits.
|
[Advertisement]
|
What's New at ZERO
New Members Elected to ZERO's Board of Directors
Dr.
Sanford “Sandy” Siegel of Baltimore, MD and Mrs. Sherry S. Galloway of
Albuquerque, NM are 
new members of ZERO’s Board of Directors.
Dr. Siegel is the President and CEO of Chesapeake Urology Associates, the largest urology practice in Maryland and the Mid-Atlantic Region with 16 urology centers, the Prostate Center, the Incontinence Center and 14 surgical centers throughout the greater Baltimore, Maryland area. Dr. Siegel initiated the Chesapeake Urology Scholarship Program and was a leader in establishing the Chesapeake Urology Scholar through the American Urological Association Foundation. In 2007, he led the formation of the “Great Prostate Cancer Challenge” (GPCC) to raise money and awareness for prostate cancer research. GPCC 5K races, in partnership with ZERO’s DASH FOR DAD race series, represent the premier men’s health race event in the U.S. which is coming to 12 cities this year and engaging more than 6,000 runners and 10,000 volunteers, spectators and supporters. Dr. Siegel graduated from the University of Maryland School of Medicine and received specialty training at Temple University Hospital in Philadelphia. He has practiced urology in the Baltimore area for more than 20 years and is certified by the American Board of Urology.
Mrs. Galloway (shown in photo with her son, Jeremy) is a
registered nurse. She received an
A.A. in registered nursing and a B.A. in psychology. She worked as an emergency
room nurse for almost 30 years and then attended Esalen Institute in Big Sur,
CA, where she studied massage therapy. She later relocated to Albuquerque where she taught medical massage at
the New Mexico Academy of Healing Arts in Santa Fe. Currently, she works as a registered nurse and also teaches
at the Central New Mexico City
College system which has five campuses. Her work involves informing the student population about various
diseases, particularly cancer, and teaching awareness. Mrs. Galloway directly experienced the impact of prostate
cancer as her husband had the disease in his late 40s. Her only son, 36-year-old Jeremy, died
from prostate cancer in 2007 after an 18-month struggle. Mrs. Galloway became
involved with ZERO during the period of her son’s illness when she would
contact the organization for information and support. She joined ZERO’s Founders Club and attended ZERO’s annual
Summit to End Prostate Cancer in Washington, D.C. She plans to write a book about her son’s story to raise
public awareness of prostate cancer and the need for increased research to find
a cure.
Hearing Set to Push for Increased Research Funding for Prostate Cancer
The House Appropriations Defense subcommittee will convene a public witness hearing on May 20 at 10:00am in room H-140 of the U.S. Capitol. The hearing is expected to feature testimony regarding programs of the Congressionally Directed Medical Research Program (CDMRP).
Sherry Galloway, RN and Jonathon W. Simons, MD will testify to make the case for increased research funding for the Prostate Cancer Research Program. Sherry, a registered nurse and ZERO board member, has had an intimate experience with prostate cancer as her husband is a 6-year survivor and her son died with advanced metastatic prostate cancer at the age of 36. Dr. Simons is CEO and president of the Prostate Cancer Foundation. He will present testimony focusing on the scientific needs of the prostate cancer community.
To view Mrs. Galloway's prepared testimony, click here.- To view Dr. Simons' prepared testimony, click here.
'DASH FOR DAD' Race Series Coming to 12 Cities to Raise Prostate Cancer Awareness
As National Race Series Expands Across U.S. in 2010, Supporters Are Encouraged to Bring This Event to Their City
Lace up your sneakers and join us in the race to end prostate cancer!
DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.
ZERO - The Project to End Prostate Cancer, with sponsors from across the country, has grown the DASH FOR DAD and its partner races - the Great Prostate Cancer Challenge® - to include 12 cities and an expected 6,000 runners competing in 2010.
The DASH FOR DAD or partnering Great Prostate Cancer Challenge® 5K will be held in the following cities:
 |
||
- Albuquerque, NM - Nov. 2010
- Baltimore, MD - Sept. 26
- Buffalo, NY - Sept. 19
- Central FL - Oct. 23
- Columbus, OH - Aug. 29
- Harrisburg, PA - Sept. 10
- Indianapolis, IN - Sept. 18
- Kansas City, MO - Sept. 19
- Memphis, TN - Sept. 11
- Nashville, TN - Sept. 11
- New York, NY (Long Island) - Nov. 14
- Washington, DC (Alexandria, VA) - Sept. 26
Since the national race series began in 2008, more than $1 million has been raised to promote prostate cancer awareness, early detection and research. Many runners create teams and collect monetary pledges from family and friends to boost funding for local prostate cancer services.
Hosting a DASH FOR DAD is a significant way to promote prostate cancer awareness in your area - and there is still time to bring this race to your city!
Urology medical practices and other supporting organizations are especially encouraged to organize a DASH FOR DAD, due to the importance of providing free prostate cancer testing and promoting research for a cure. Click here to download the DASH FOR DAD race application.
"DASH FOR DAD elevates prostate cancer awareness to a broader nationwide level," said ZERO's CEO Skip Lockwood. "We all know someone who is impacted by this most commonly diagnosed cancer among men, striking one in every six. That's why we must do all that we can to put an end to this horrible disease."
For more information about the DASH FOR DAD 10K or if you're interested in hosting a DASH FOR DAD run to your city, contact Tracy Cesaretti.
Join ZERO's DASH FOR DAD Endurance Team at the Marine Corps Marathon on Sunday Oct. 31
 |
||
Be a pioneer. Be a fighter. Be a winner. Help end prostate cancer!
The renowned Marine Corps Marathon in Washington, D.C. begins and ends at the world-famous Marine Corps War Memorial, passing the Lincoln, Jefferson and Washington memorials along the race route.
The People's Marathon" attracts runners from all over the world – young and old, first-time marathoners and veterans – who compete in this endurance race for their own personal goals.
Now you can join the fight to end prostate cancer.
All participants receive
guaranteed entry into the race, a technical training shirt, fundraising website
and advice, and a pre-race dinner. Please commit to raise a minimum of $1,000
to help ZERO end prostate cancer. Participants who are traveling to Washington,
D.C. for the event and raise $2,000 will receive a $500 travel reimbursement. Click here for more information and sign up today!
Other ZERO DASH FOR DAD Endurance Teams:
Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
 |
||
You can make a positive impact this Fall by representing ZERO and the entire prostate cancer community in Washington, D.C.
Registration for the 2010 "Summit to End Prostate Cancer" is now open!
This 2010 Summit, scheduled for September 14-16, will focus on effective strategies for increasing the Federal investment in prostate cancer research. During the Summit, participants will have the opportunity to meet with their elected officials on Capitol Hill and learn more about the federal legislative process.
Let Congress Know Your Concerns
We encourage you to contact your elected representatives on Capitol Hill to indicate your support for early detection, men's prostate health and the need for research funding to improve early diagnosis of prostate cancer.
|
[Advertisement]
|
Research and Treatment Update
Prostate Cancer Surveillance: Biopsy Findings Appear Indispensable
Surveillance biopsy – not PSA velocity and PSA doubling time – is the test clinicians should rely on to determine when men with low-risk cancer are in need of treatment, this study indicates.
Taxane Analog Shows 'Unequivocal Benefit' in Prostate Mets
Cabazitaxel, an investigational taxane, significantly extends survival among prostate cancer patients whose disease has progressed despite hormone therapy.
Positive Surgical Margins and Prostate
Cancer-Specific Mortality
This study is said to be the first to suggest a definitive link between positive surgical margins (PSMs) following radical prostatectomy and an increased risk for prostate cancer-specific mortality (PCSM).
New Technology Aids in Prostate Cancer Treatment
Advanced accuracy in detecting a gene called PTEN, which is associated with aggressive prostate cancer, can improve the way doctors manage prostate cancer treatment, this research shows.
PSA Standardization DVD: